These results are consistent with a study showing that acute effects of CE3F4 treatment, an EPAC1 selective inhibitor (Courilleau et al., 2012; Courilleau et al., 2013), shorten the duration of AF in mice (Prajapati et al., 2019). The gene discussed is RAPGEF3; the disease is atrial fibrillation.